Scilex Holding Company has closed the second tranche of its strategic investment in Datavault AI, exercising a pre-funded warrant for 263,914,094 shares that Datavault stockholders approved on November 24, 2025. The transaction, funded in Bitcoin at the spot rate set at signing, gives Scilex a stake valued at approximately $583.3 million based on Datavault’s $2.21 closing price on November 25, 2025. The two companies plan to accelerate collaboration in 2026 around real-world asset tokenization and data monetization.
The move is a striking pivot for a non-opioid pain company best known for ZTlido, Elyxyb, and Gloperba, and a late-stage pipeline in sciatica, acute low back pain, and fibromyalgia. Rather than another traditional pharma-digital partnership, Scilex is buying into the underlying data infrastructure and economics, and doing so through a crypto-denominated structure that signals comfort with volatility in pursuit of asymmetric upside. The strategic question for Commercial and Medical leaders is whether owning a portion of the data rails can materially strengthen market access, label expansion, and lifecycle strategies—or distract from core execution in crowded pain markets.
This matters now because real-world evidence is becoming the currency of contracting and differentiation, especially in pain where payer scrutiny around functional outcomes, adherence, and opioid-sparing impact remains intense. If Datavault’s stack can tokenize consents, provenance, and outcomes—creating tamper-evident data objects that link patient-reported outcomes, device signals, and claims—Scilex could sharpen arguments for coverage, step edits, and value-based arrangements. For patients, the model hints at mechanisms to transparently value and permission their data. For payers, immutable audit trails and near-real-time analytics may reduce adjudication friction in outcomes-based contracts. For HCPs, the promise is streamlined evidence capture that feeds back into clinical decision support without increasing burden. Competitors should note that this is not a sponsor–vendor contract; it is an equity bet to influence the evolution of data liquidity that could become a competitive moat.
The investment also tracks several industry currents. Biopharma is moving from episodic RWE projects to continuous evidence generation, requiring trusted pipelines for consent, identity, and provenance. Tokenization—attaching unique digital identities to datasets, consents, and even serialized product units—aligns with tighter requirements for DSCSA compliance, 340B integrity, chargeback reconciliation, and post-market safety. As capital markets remain selective for mid-cap specialty players, cross-industry equity stakes and alternative financing, including digital assets on corporate balance sheets, are re-emerging as tools to fund growth without traditional dilution. Meanwhile, regulators are pressing interoperability and data governance, making data traceability table stakes for HCEI communications and payer dossiers.
Execution risk is real. Crypto-denominated exposure adds balance-sheet volatility, and Datavault operates outside traditional healthcare incumbency, which raises integration, privacy, and compliance challenges. The value of tokenized RWE will hinge on rigorous consent management, alignment with HIPAA and state privacy laws, and acceptance by payers and regulators that provenance guarantees translate into evidentiary quality. Medical Affairs will need to define study architectures where tokenization demonstrably improves data integrity, not just portability, and Commercial teams must convert those gains into contract structures that payers will sign.
The near-term signal to watch is whether Scilex pilots tokenized outcomes programs around its in-market brands—migraine freedom windows for Elyxyb, neuropathic pain function scores for ZTlido, or flare rates and adherence for Gloperba—and secures payer recognition for these datasets in coverage decisions. If tokenized evidence moves the needle in access or rebates, expect more sponsors to take equity positions in data infrastructure rather than rent it. If not, this could be remembered as an ambitious hedge that blurred focus at a critical time in pain-market competition.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
